A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

Zeeshan Javed, Maria Papageorgiou, Harshal Deshmukh, Eric S. Kilpatrick, Vincent Mann, Lynsey Corless, George Abouda, Alan S. Rigby, Stephen Atkin, Thozhukat Sathyapalan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L, FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001). Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.

Original languageEnglish
JournalNutrients
Volume11
Issue number1
DOIs
Publication statusPublished - 17 Jan 2019

Fingerprint

polycystic ovary syndrome
Polycystic Ovary Syndrome
vitamin D
Vitamin D
risk factors
Randomized Controlled Trials
hormones
Hormones
liver
Liver
insulin resistance
placebos
Insulin Resistance
fatty liver
Placebos
Alanine Transaminase
alanine transaminase
hyaluronic acid
Sex Hormone-Binding Globulin
liver cirrhosis

Keywords

  • cardiovascular risk factors
  • hormones
  • liver markers
  • polycystic ovary syndrome
  • vitamin D

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Cite this

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. / Javed, Zeeshan; Papageorgiou, Maria; Deshmukh, Harshal; Kilpatrick, Eric S.; Mann, Vincent; Corless, Lynsey; Abouda, George; Rigby, Alan S.; Atkin, Stephen; Sathyapalan, Thozhukat.

In: Nutrients, Vol. 11, No. 1, 17.01.2019.

Research output: Contribution to journalArticle

Javed, Z, Papageorgiou, M, Deshmukh, H, Kilpatrick, ES, Mann, V, Corless, L, Abouda, G, Rigby, AS, Atkin, S & Sathyapalan, T 2019, 'A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome', Nutrients, vol. 11, no. 1. https://doi.org/10.3390/nu11010188
Javed, Zeeshan ; Papageorgiou, Maria ; Deshmukh, Harshal ; Kilpatrick, Eric S. ; Mann, Vincent ; Corless, Lynsey ; Abouda, George ; Rigby, Alan S. ; Atkin, Stephen ; Sathyapalan, Thozhukat. / A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. In: Nutrients. 2019 ; Vol. 11, No. 1.
@article{88e70688e5284ccd83878867bb55f0a9,
title = "A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome",
abstract = "Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L, FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001). Between groups comparisons ({\%} baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.",
keywords = "cardiovascular risk factors, hormones, liver markers, polycystic ovary syndrome, vitamin D",
author = "Zeeshan Javed and Maria Papageorgiou and Harshal Deshmukh and Kilpatrick, {Eric S.} and Vincent Mann and Lynsey Corless and George Abouda and Rigby, {Alan S.} and Stephen Atkin and Thozhukat Sathyapalan",
year = "2019",
month = "1",
day = "17",
doi = "10.3390/nu11010188",
language = "English",
volume = "11",
journal = "Nutrients",
issn = "2072-6643",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

AU - Javed, Zeeshan

AU - Papageorgiou, Maria

AU - Deshmukh, Harshal

AU - Kilpatrick, Eric S.

AU - Mann, Vincent

AU - Corless, Lynsey

AU - Abouda, George

AU - Rigby, Alan S.

AU - Atkin, Stephen

AU - Sathyapalan, Thozhukat

PY - 2019/1/17

Y1 - 2019/1/17

N2 - Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L, FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001). Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.

AB - Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L, FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001). Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.

KW - cardiovascular risk factors

KW - hormones

KW - liver markers

KW - polycystic ovary syndrome

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=85060125593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060125593&partnerID=8YFLogxK

U2 - 10.3390/nu11010188

DO - 10.3390/nu11010188

M3 - Article

C2 - 30658483

AN - SCOPUS:85060125593

VL - 11

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 1

ER -